Adults (n=50) | |
---|---|
A | |
Malignancy | 24 (48%) |
Neuromuscular degenerative disorder | 8 (16%) |
Stroke | 4 (8%) |
Respiratory disease | 4 (8%) |
Brain injury | 3 (6%) |
Congenital malformation | 3 (6%) |
Unknown | 4 (8%) |
Children (n=37) | |
B | |
Chromosomal/metabolic disorder | 9 (24.3%) |
Cerebral palsy | 7 (18.9%) |
Cystic fibrosis | 5 (13.5%) |
Developmental delay | 5 (13.5%) |
Congenital heart disease | 4 (10.8%) |
Chronic kidney disease | 2 (5.4%) |
Gastrointestinal tract congenital malformation | 2 (5.4%) |
Malignancy | 1 (2.7%) |
Unknown | 2 (5.4%) |
Patients were asked to complete the indication for initial prescription of HEN as part of the distributed questionnaire. A: Data are displayed as actual and percentage count of adult (n=50) and B: Paediatric (n=37) patients.